The BIOMETSCO project aimed to find biomarkers that can help predict whether or not a patient with colorectal cancer also has occult metastases. If present, these small and undetectable metastases currently pose a significant threat to the patient’s survival rate.
The team used a two-step process combining bulk analysisand spatial transcriptiomics of different tissue samples to compare cancer and normal tissue. During the project, the BIOMETSCO team identified several potential biomarkers, genereated a lot of data as well as applied for (and received) a grant to continue one aspect of the ODIN project in a new project with new .partners.
On this page you can can watch a video recorded at the beginning of the project. You can also read an article on the output of the project and you can find lists of project participants and articles published by the BIOMETSCO team.
We unite bright minds from industry and academia to jointly create need-driven clinical research projects - and pave the way for innovative new treatments and diagnostics. We fund the best project ideas through competitive funding calls. Although companies cannot receive funding, it is free of charge to join.
The platform is sponsored by the Novo Nordisk Foundation with 180 million DKK from 2024-2029.
You are welcome to contact us if you have questions or comments. Reach out to odin@au.dk or find the Secretariat's direct email addresses under contacts.
Although the platform spans five Danish universities, we're based in Aarhus. Our office is located at Aarhus University, Ny Munkegade 120, blg 1521-214.